MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ
49.52
-0.44
-0.88%
After Hours: 48.50 -1.02 -2.06% 19:45 04/13 EDT
OPEN
50.11
PREV CLOSE
49.96
HIGH
50.55
LOW
48.51
VOLUME
1.96M
TURNOVER
--
52 WEEK HIGH
51.63
52 WEEK LOW
27.07
MARKET CAP
5.69B
P/E (TTM)
-15.0288
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SRRK last week (0406-0410)?
Weekly Report · 19h ago
ClearBridge SMID Cap Growth initiates new positions, exits several in Q1
Seeking Alpha · 4d ago
A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk
Simply Wall St · 04/07 03:13
Weekly Report: what happened at SRRK last week (0330-0403)?
Weekly Report · 04/06 10:11
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Medtronic (MDT)
TipRanks · 04/01 17:00
Scholar Rock price target raised to $57 from $54 at Jefferies
TipRanks · 04/01 16:50
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 04/01 13:56
Scholar Rock Holding Is Maintained at Outperform by Wedbush
Dow Jones · 04/01 12:49
More
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Webull offers Scholar Rock Holding Corp stock information, including NASDAQ: SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.